Nordic ListingsIssuer Report
Episurf Medical AB: Quarterly Trading Report 2025 Q3
Episurf Medical AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=be924a35a2df36e63dbf0f54052f6f41f&lang=en&src=omxlink
Episurf Medical AB: Quarterly Trading Report 2025 Q3
Earlier from Episurf Medical
- EPIS_B: Adjusted EBIT improved, U.S. order intake surged, and a SEK 29.4m rights issue is planned
- EPIS_B: Record Q1 sales and US growth position Episurf for accelerated expansion and improved results
- EPIS_B: Net sales grew, losses narrowed, and US market expansion accelerated, supported by new funding
- EPIS_B: Q3 saw improved results, US expansion, and strong order growth; 510(k) clearance expected 2025
- EPIS_B: Strong sales growth and improved losses as US expansion and cost savings accelerate
Later from Episurf Medical
- EPIS_B: US growth and cost savings drive improved results, but financing uncertainty persists
- Episurf's Implants Market Approved In Singapore
- Episurf Acquires Real Estate Assets, Forms New Business Segment
- Episurf Acquires Properties From Klarabo
- EPIS_B: Operating losses narrowed as sales grew and real estate investments began, but financing risks remain
Follow Episurf Medical into a list and get an email when it puts out news.
Follow Episurf Medical